Related Experiment Video
Updated: Aug 29, 2025
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
832
Hypercoagulability in COVID-19: from an unknown beginning to future therapies
Ştefania-Teodora Duca1,2, Alexandru-Dan Costache1,2, Radu-Ştefan Miftode1,2
1Department of Medical Specialties I, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy Iasi, Romania.
Medicine and Pharmacy Reports
|September 5, 2022
Summary
Coronavirus disease 2019 (COVID-19) causes severe inflammation and blood clots. Understanding the link between inflammation and coagulopathy is key to developing new treatments for COVID-19 patients.
Area of Science:
- Hematology
- Immunology
- Infectious Diseases
Background:
- Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, presents with severe inflammation and coagulopathy.
- Initially viewed as a respiratory illness, COVID-19 is now recognized to induce a pro-inflammatory and hypercoagulable state.
Purpose of the Study:
- To explore the mechanisms linking inflammation and coagulopathy in COVID-19.
- To highlight the significance of hematological parameters in predicting COVID-19 outcomes.
- To discuss the role of anticoagulation and the need for alternative therapies.
Main Methods:
- Review of existing literature on COVID-19 pathophysiology.
- Analysis of hematological parameters, including D-dimers and fibrinolytic products.
- Examination of mechanisms such as cytokine storm and endothelial dysfunction.
Main Results:
- Elevated D-dimer levels are indicative of massive fibrin formation and are an independent risk factor for mortality.
- COVID-19 is associated with increased fibrinogen, exhausted fibrinolysis, and endothelial dysfunction.
- Prophylactic anticoagulation is recommended for hospitalized COVID-19 patients, with higher doses for those at increased risk.
Conclusions:
- The interplay between inflammation and coagulopathy in COVID-19 is complex and critical.
- Effective management requires a thorough understanding of these interconnected processes.
- Further research is needed to develop targeted interventional strategies beyond anticoagulation.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
861
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
861
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:29Venous Thrombosis III: Interprofessional Care
18
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
01:09Coagulation
7.3K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.3K
01:24Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
29
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
29